30-03-2025
Asian Market Value Stock Estimates For March 2025
As global markets grapple with economic uncertainty and inflation concerns, the Asian markets have shown resilience, with investors keenly eyeing value stocks that may offer stability amid volatility. In this context, identifying undervalued stocks in Asia could provide opportunities for those looking to navigate these challenging times by focusing on companies with strong fundamentals and potential for growth.
Name
Current Price
Fair Value (Est)
Discount (Est)
DIP (TSE:2379)
¥2299.00
¥4575.97
49.8%
Zhejiang Cfmoto PowerLtd (SHSE:603129)
CN¥183.48
CN¥359.71
49%
Consun Pharmaceutical Group (SEHK:1681)
HK$8.95
HK$17.64
49.3%
Chison Medical Technologies (SHSE:688358)
CN¥31.17
CN¥61.59
49.4%
RACCOON HOLDINGS (TSE:3031)
¥965.00
¥1893.98
49%
TechnoPro Holdings (TSE:6028)
¥3301.00
¥6597.88
50%
S Foods (TSE:2292)
¥2544.00
¥5084.09
50%
Com2uS (KOSDAQ:A078340)
₩45950.00
₩91675.96
49.9%
Siam Wellness Group (SET:SPA)
THB4.58
THB9.12
49.8%
Akeso (SEHK:9926)
HK$74.60
HK$147.04
49.3%
Click here to see the full list of 276 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.
Let's review some notable picks from our screened stocks.
Overview: PharmaResearch Co., Ltd., along with its subsidiaries, is a biopharmaceutical company operating mainly in South Korea with a market cap of approximately ₩3.51 trillion.
Operations: PharmaResearch Co., Ltd.'s revenue segments are not detailed in the provided text.
Estimated Discount To Fair Value: 15.4%
PharmaResearch is trading at ₩337,500, below its estimated fair value of ₩398,985.63. With forecasted revenue growth of 20.4% per year outpacing the Korean market's 8.1%, and earnings expected to grow significantly at 26.8% annually, the stock appears undervalued based on cash flows despite not being highly undervalued by a significant margin. Recent dividend increases further reflect confidence in its financial health and future prospects.
Our comprehensive growth report raises the possibility that PharmaResearch is poised for substantial financial growth.
Click to explore a detailed breakdown of our findings in PharmaResearch's balance sheet health report.
Overview: Seres Group Co., Ltd. is engaged in the research, development, manufacturing, sale, and supply of automobiles and auto parts in China with a market capitalization of CN¥191.38 billion.
Operations: The company's revenue from the automobile industry amounts to CN¥125.79 billion.
Estimated Discount To Fair Value: 17.6%
Seres Group Ltd. is trading at CN¥127.08, below its estimated fair value of CN¥154.2, indicating it is undervalued based on cash flows though not by a significant margin. The company's earnings are forecast to grow significantly at 33.6% annually, outpacing the Chinese market average of 25%. With revenue growth expected at 16.2% per year and a high forecasted return on equity of 33.7%, Seres demonstrates strong financial potential despite recent profitability challenges.
The growth report we've compiled suggests that Seres GroupLtd's future prospects could be on the up.
Unlock comprehensive insights into our analysis of Seres GroupLtd stock in this financial health report.
Overview: Wuhan Keqian Biology Co., Ltd specializes in the R&D, production, sales, and technical services for animal epidemic prevention through veterinary biological products in China, with a market cap of CN¥7.36 billion.
Operations: The company's revenue primarily comes from the Veterinary Biological Products Industry, amounting to CN¥947.87 million.
Estimated Discount To Fair Value: 29.2%
Wuhan Keqian Biology Ltd. is trading at CN¥15.84, significantly below its estimated fair value of CN¥22.38, highlighting its undervaluation based on cash flows. The company forecasts robust revenue growth of 22.8% annually, surpassing the Chinese market's average growth rate of 13%. Despite a recent decline in sales and net income for 2024, earnings are projected to grow at approximately 21% per year over the next three years, though slower than the market's expected pace.
Insights from our recent growth report point to a promising forecast for Wuhan Keqian BiologyLtd's business outlook.
Delve into the full analysis health report here for a deeper understanding of Wuhan Keqian BiologyLtd.
Embark on your investment journey to our 276 Undervalued Asian Stocks Based On Cash Flows selection here.
Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSDAQ:A214450 SHSE:601127 and SHSE:688526.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
